The molecular basis of anticancer and apoptotic effects of R-goniothalamin (GON), a plant secondary metabolite was studied. We show that induction of oxidative stress and reactivation of mutant p53 underlie the strong cytotoxic effects of GON against the breast cancer cells. While GON was not toxic to the MCF10a breast epithelial cells, the SKBR3 breast cancer cells harboring an R175H mutant p53 were highly sensitive (IC 50 = 7.3 µM). Flow cytometry and other pertinent assays showed that GON-induced abundant reactive oxygen species (ROS), glutathione depletion, protein glutathionylation and activation of apoptotic markers. GON was found to conjugate with glutathione both in vitro and in cells and the product was characterized by mass spectrometry. We hypothesized that the redox imbalance induced by GON may affect the structure of the R175H mutant p53 protein, and account for greater cytotoxicity. Using the SKBR3 breast cancer and p53-null H1299 lung cancer cells stably expressing the R175H p53 mutant protein, we demonstrated that GON triggers the appearance of a wild-type-like p53 protein by using conformation-specific antibodies, immunoprecipitation, DNAbinding assays and target gene expression. p53 restoration was associated with a G2/M arrest, senescence, reduced cell migration, invasion and increased cell death. GON elicited a highly synergistic cytotoxicity with cisplatin in SKBR3 cells. In SKBR3 xenografts developed in nude mice, there was a marked tumor growth delay by GON alone and GON + cisplatin combination. Our studies highlight the impact of tumor redox-stress generated by GON in activating the mutant p53 protein for greater antitumor efficacy.
Introduction
Epidemiologic, clinical and experimental evidence suggests that ingestion of certain culinary herbs and spices is associated with reduced cancer risk. This has generated great interest in defining and exploiting the relatively nontoxic bioactive components of the natural products for possible use in cancer prevention and/or treatment (1) . In this regard, the styryl lactone (R,E)-6-styryl-5,6-dihydro-2H-pyran-2-one, called goniothalamin (GON) found in members of a tropical tree called Goniothalamus, has gained much attention. Although there are about 160 species of this genus distributed across Southeast Asia, only a handful of species including the Goniothalamus macrophyllus have been recognized for their medicinal properties (2) . The fruit and seed extracts and/or decoctions of GON have been used for ages for treatment of asthma, rheumatism, malaria, stomach ache, as a postpartum protective remedy and an antidote for poisons (3) . Goniothalamus species accumulate a series of acetogenins and styryl lactones as secondary metabolites (4) . GON has been studied by many researchers for its anticancer, anti-inflammatory and apoptotic effects (5, 6) . It has been reported to kill multiple types of cancer cells while sparing the normal cells including blood cells. GON was shown to be selectively cytotoxic to ovarian cancer cells (Caov-3) without killing the MDBK normal kidney cells in comparison with tamoxifen or taxol (7) . GON has been reported to exert antiproliferative activity against many solid tumors with no evidence of toxic effects in the animals after single or repeated doses (8) . Unspecified DNA damage, cell cycle arrest and cell death have been implicated in the anticancer effects of GON (9) . Nevertheless, the precise mechanisms of cytotoxic effects of this important plant metabolite remain unclear.
The transcription factor p53 plays essential regulatory roles in protecting the emergence of oncogenic genomes by inducing cell cycle arrest and/or apoptosis in response to various forms of cellular stresses and DNA damage (10, 11) . Abrogation of p53 function occurs in almost all human cancers with a wide range of mutation frequencies (12) (13) (14) . The majority of the inactivating mutations occur in the central core of DNA binding domain (DBD) of p53. These mutations can be DNA contact mutations exemplified by R248Q and R273H, where the mutation alters a residue involved in making contact with DNA, and conformational mutants like R175H, which affect the stability of the DBD, resulting in the loss of function (14) . Tumors harboring p53 mutations are resistant to conventional chemo and radiotherapies (15) , and often have a gain of function phenotype, promoting cell growth and tumorigenicity (16, 17) . Therefore, reactivation of mutant p53s to their active forms might provide successful anticancer treatment modalities. There is currently a huge interest in designing small molecules and engineering strategies for this objective (18) (19) (20) . Recently this strategy led to the identification of molecules like PRIMA (21) , MIRA-1 (22) , CP-31398 (23), STIMA-1 (24), SCH529074 (25) , NSC319726 (26) and others (27) (28) (29) (30) . Our laboratory in previous studies showed that mutant p53 proteins can be reactivated in conditions of redox imbalance (31, 32) . The current study examined the anticancer mechanisms of GON and we show the generation of ROS and subsequent restoration of functional activity of the R175H mutant p53 underlies the tumor selective cytotoxicity.
Materials and methods
Human cancer cell lines MCF7, SKBR3, MDA-MB-231, MDA-MB-468, H1299 cells and MCF10A (normal breast epithelial cells) were purchased from The American Type Culture Collection (ATCC), a public repository. All cell lines were used within 5 months of their acquisition. ATCC routinely verifies the identity of cell lines by short tandem repeat (STR) profiling. The antibody sources were: p53 PAB1620, p53 PAB240 (Millipore), P21, PUMA, glutathione, BAX, actin, GAPDH (Cell Signaling), DEP1, NTAL and Styx (Santa Cruz Biotechnology). (R) and (S)-GON were synthesized and purified as described previously (33) .
Cell viability and cytotoxicity assays
Cytotoxicity was evaluated following a continuous 72 h drug exposure using the resazurin reduction assay as described previously (31) . For DCF-DA and PI staining, cells were plated for 24 h and then subjected to GON exposure. For colony formation assay, cells were seeded in six-well plates at 1 × 10 3 cells per well, treated with GON for 24 h, and further incubated for another 10 days.
Assays for ROS determination

Flow cytometry
Cells were trypsinized, the single cell suspensions in culture media were stained with 20 μM DCFDA or DHE for 30 min at 37°C. In some cases, NAC or Tyron was used for quenching the ROS. The cells were analyzed using a BD Biosciences FACSVERSE instrument.
Immunofluorescence
DCFDA or DHE was added to cells grown in phenol red minus media followed by 30 min incubation. They were next treated with GON for 4 h. Images were obtained using a Nikon fluorescence microscope.
Flow cytometry for detection of wt-p53 in SKBR3 cells using pAb1620 SKBR3 cells were untreated or treated with 25 μM GON for 12 h. Cells were trypsinized, washed and fixed in 4% formaldehyde/PBS for 10 min. Next, they were chilled and drops of cold methanol added for permeabilization. The cells were washed and suspended in 100 μl of diluted primary antibodies (pAb 1620 and isotype control IgG2a at 1 µg/ml in 0.5% BSA) for 1 h and FITC-conjugated secondary antibodies for 30 min followed by flow cytometry. A similar procedure was used for immunofluorescence of other proteins.
Immunoprecipitation combined with immunoblotting
p53 immunoprecipitations were performed using conformationally specific monoclonal antibodies pAb 1620 (wild-type) and pAb 240 (mutant) as described previously (31) . The complexes were washed, solubilized in SDSsample buffer, and electrophoresed on 10% SDS-polyacrylamide gels. The proteins were transferred to the PVDF membranes and p53 monoclonal antibody DO-1 was used for detecting the total p53 protein.
Electrophoretic-mobility shift assay (EMSA)
The Signosis p53 EMSA assay kit was used according to the manufacturer's instructions. Nuclear extracts from control and GON treated SKBR3 cells were prepared as described (31) . The reaction mixtures containing 2 μg nuclear extract, 1 μl poly d(I-C), 2.0 μl of 5X Binding Buffer (20 mM HEPES, pH 7.9, 1 mM DTT, 0.1 mM EDTA, 50 mM KCl, 5 % Glycerol) and 400 ng 22-mer duplex biotinylated p53 recognition sequence were incubated at 30°C for 20 min. The samples were then resolved on 6.5% non-denaturing polyacrylamide gels prepared in 45 mM Tris-borate/1 mM EDTA buffer. The DNA was transferred to nylon membranes, blocked with 2% nonfat dry milk and probed with Streptavidin-HRP.
Analysis of cellular GSH levels
The amount of GSH in cell lysates was quantified by Ellman's reagent and absorbance measurement at 405 nm using a microplate reader (34) .
Annexin V-FITC detection of apoptosis
Tumor cells were harvested, washed and resuspended in 100 μl of binding buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 4% BSA). The cell suspensions (100 μl) were then incubated with 5 μl of Annexin V-FITC (BD Bioscience) and 10 μl (50 μg/mL) of PI for 30 min. The population of Annexin V-positive cells was evaluated by flow cytometry.
Effect of GON on tumor cell invasion and migration
These assay procedures are described in Supplementary Information 
Senescence-associated β-galactosidase staining
The staining for senescence-associated β-galactosidase (SA-β-gal) was performed using a kit from Cell Signaling. The SKBR3 cells were treated with GON (5 μM, 24 h), replaced with fresh media. After 48 h, the cells were fixed and stained for SA-β-gal activity.
Development of the SKBR3 xenografts and drug administration
To establish the SKBR3 xenografts, a total of 5 × 10 6 cells in 0.1 ml were subcutaneously injected into the left inguinal area of the female athymic nude mice. When the tumor volume reached ~40 mm 3 , the tumor-bearing mice were randomly divided into the treatment and control groups (6 mice/group). GON (10 mg/kg), cisplatin (5 mg/kg) was administered alone or in combination by i.p. injections weekly for about four weeks. Tumor volumes were measured with Vernier calipers. The xenografted tumors were also excised and weighed at the end.
Statistics
All experiments were repeated at least three times independent of each other, and the mean results or representative blots are presented.
Statistical differences between groups were assessed by Student's t-test. p < 0.05 was used as the criterion for statistical significance.
Results
R-GON but not the S-enantiomer selectively kills breast cancer cells but not normal cells
To determine the enantiomeric specificity of GON in its anticancer effects, the R and S forms of GON were synthesized as described (33) in Supplemental Information and their antiproliferative effects against the SKBR3 breast cancer cells determined. Compared to its naturally occurring R-GON ( Figure 1A ), the S-GON was 3-fold less effective in cell killing (IC 50 21 µM versus 7.3 µM), suggesting some specificity. All studies described here were performed using the R-form. Interestingly, three other studies have also revealed the superior cell killing by the R-enantiomer of GON compared to the S-form (35) (36) (37) . The cytotoxicity of GON was tested against several human breast cancer (BC) cell lines (MCF7, SKBR3, MDA-MB-231 and MDA-MB-468) and normal cells (MCF 10A) using the resazurin reduction assay ( Figure 1B and C). GON markedly induced death of cancer cells, while the viability of MCF-10A breast epithelial cells was affected only minimally at the highest concentrations used ( Figure 1D ). The IC 50 of GON in BC cells was in the range of 7-20 μM. Cytotoxicity assay showed that the rate of cell death was significantly increased in BC cells after 48 h of GON treatment and this occurred in a concentration-dependent manner. The cytotoxicity of GON was blocked by pretreatment with the antioxidant NAC, indicating that GON selectively kills breast cancer cells, in which an active response to oxidative stress occurs ( Figure 1C ). Staining of the dead SKBR3 cells by PI further confirmed this concentration dependence ( Figure 1E ). Taken together, these data suggest that GON displayed potent and selective cytotoxic activity against the SKBR3 cell line, which harbors an allele-specific R175H mutation of p53 as compared to the wt p53 expressing cells (MCF7), other p53 mutants (MDA-MB-231 and MDA-MB-468) and normal cells (MCF-10A).
Clonogenic survival assays to assess the effect of GON on colony formation of SKBR3 cells were also performed. GON greatly reduced the size and number SKBR3 cell colonies ( Figure 1F ).
Goniothalamin increases ROS accumulation
Because GON contains a potentially electrophilic double bond in its structure, the question whether it induces oxidative stress by depleting the antioxidant thiols through an electrophilic substitution was investigated. The chemical reactivity of GON was evaluated using glutathione (GSH) as a representative thiol nucleophile. Treatment of GON with two equivalents of GSH in vitro generated a conjugate addition product at the double bond ( Figure 2A and Supplementary Figure 1A , available at Carcinogenesis Online) and the structure of the GON-GSH complex was confirmed by Electrospray Ionization-Mass Spectrometry (Supplementary Figure 1B , available at Carcinogenesis Online). An identical GON-GSH adduct was also found to occur in SKBR3 cells exposed to GON; this was demonstrated by mass spectral analysis as well (data not shown). These results shed light on the mechanistic aspects of oxidative stress induced by GON in breast cancer cells.
To substantiate the thiol depletion, the levels of GSH and GSSG were quantitated in SKBR3cells treated with GON for 3 h. As shown in Figure 2B , GON exposure resulted in a significant reduction of the GSH levels and slight increases in GSSG levels in a concentration-dependent manner. More than half of GSH was depleted by GON at doses higher than 25 μM. The elevation GSSG was accompanied by a marked reduction in NADPH levels ( Figure 2C ).
In view of the redox alterations above, we measured the induction of ROS by GON after 3 h exposure using fluorescence microscopy and flow cytometry. The redox-sensitive dyes CM-H2DCF-DA and DHE, which show selective sensitivity to the hydroxyl and superoxide radicals respectively (38) . GON exposure resulted in a rapid and abundant generation of ROS as revealed by a significant increase in fluorescence due to both DCFDA ( Figure 2D ) and DHE ( Figure 2E ). Flow cytometry in SKBR3 cells exposed to GON similarly showed a greater generation of ROS in response to the fluorescent redox dyes; in cells exposed to DCFDA or DHE, there were distinct peak shifts in the spectra, compared to the untreated controls (right panels of Figures 2D  and 2E ). Pretreatment of cells with NAC (3 mM) or Tyron, which reduce and quench the ROS and superoxides (38) attenuated the ROS production by GON, highly suggesting that an altered redox dynamics is a key mechanism of the plant metabolite.
Protein Glutathionylation
Protein thiolation, a hallmark of oxidative stress (39) , is a posttranslational modification involving the formation of mixed disulfide bonds between the reactive cysteines on protein surfaces and cellular thiols such as the GSH or free cysteine. Therefore, protein glutathionylation was assayed in response to GON using an anti-GSH antibody that recognizes GSH-conjugated proteins. We observed a significant increase in protein glutathionylation after GON treatment in SKBR3 cells by immunofluorescence ( Figure 2F ). The observation was further confirmed by western blotting, where, GON treated cell lysates showed a de novo or increased glutathionylation of numerous proteins as reflected by enhanced band densities in comparison with the untreated cells ( Figure 2G ).
Restoration of wt like conformation to the p53
R175H
Among the p53 mutants tested, the SKBR3 cells, which bear p53 R175H mutation were most preferentially killed by GON ( Figure 1B) . To further corroborate this finding, we engineered the p53-null H1299 lung cancer cells to express the R175H and R273H p53 mutant proteins. The plasmids, pLenti6/V5-p53_ R175H and pLenti6/V5-p53_R273H from the Addgene Company were used to generate the lentiviral particles and the H1299 stable transfectants selected on blasticidin. The cytotoxicity of GON was evaluated on these cell lines and indeed, both the 175 and 273 mutations were highly sensitive to the styryl-lactone ( Figure 3A ). Again, NAC was able to reduce the cytotoxic effects suggesting the ROS as the key mediator.
Using two compounds that induced mild-redox-imbalance, our previous studies demonstrated that an intracellular oxidative milieu confers transcriptional activity to the mutant proteins (31, 32) . Similarly, other small molecules reported reactivating the mutant p53 proteins also possess electrophilic centers that can react and deplete cellular thiols (21) (22) (23) (24) . Therefore, we used a number of approaches to validate the functionalization of R175H p53 mutant. First, the conformation-specific monoclonal antibodies pAb1620 and pAb240 which specifically recognize the wildtype and mutant p53 respectively were used. We performed flow cytometric analysis of p53 in permeabilized SKBR3 cells pAb1620, which binds an epitope in the DNA-binding domain of wt p53, but not to the mutant protein (40) . As shown in Figure 3B , the background fluorescence observed with isotype IgG and pAb1620 were similar in control cells, but a distinct shift was noted in GONtreated cells indicating a conformational change in the mutant p53. The reactivation of p53 was confirmed by immunofluorescence studies; as expected, the untreated SKBR3 cells showed a clear signal for mutant p53 on incubation with pAb240 with no reactive protein for pAB1620. However, GON treatment resulted in the reactivity to the pAb1620 antibodies with a corresponding decrease in pAB240-reactivity ( Figure 3C ). Immunofluorescence staining in H1299 lung cancer cells expressing the p53 R175H mutant protein with pAB1620 and pAB240 showed a similar trend with the appearance of wild-type like protein in H1299 lung cancer cells expressing the p53 R175H mutant protein ( Figure 3D ).
Further evidence for the presence of a p53 protein with wildtype immunoreactivity was obtained by immunoprecipitation of cell lysates. For this, the SKBR3 cells or H1299 cells expressing the R175H p53 were exposed to 20 µM GON for 12 h, the lysates were immunoprecipitated with the pAb 1620 or pAb240. The immune complexes were Western blotted and probed with the p53-DO1 monoclonal antibody which recognizes both the wild-type and mutant p53 proteins. The results are shown in Figure 3E and F. In both cell lines treated with GON, there was an increase in the wildtype-like p53 and a significant decrease in the mutant p53 protein, whereas the total p53 protein as detected by the DO1 antibody remained at similar levels in control and treatment groups. We suggest that the results can be explained by conformational changes occurring at the p53 protein level in an oxidative cellular milieu. 
Restoration of p53 DNA binding and transcriptional function
To determine the transcriptional competency of the wild-typelike p53 generated in GON treated SKBR3 and H1299 (p53 R175H ) cells, the binding of p53 to its recognition sequence using a biotinylated ds-DNA probe followed by EMSA. Figure 3G shows that the mutant p53 (R175H) present in the nuclear extracts (NE) from untreated cells failed to bind with DNA, whereas the NE from GON treated cells showed significant and specific binding that was diminished after adding the non-biotinylated (cold) probe. Furthermore, to assess whether the biological functions of normal p53 were restored and the p53 target genes were transactivated in SKBR3 and H1299 (p53 R175H ) cells, the expression of p21cip1, BAX and PUMA protein was quantitated after GON treatment in both SKBR3 and H1299 (p53 R175H ) cells. Indeed, the protein levels of all these established target genes of p53 were increased by GON in a concentration-dependent manner ( Figure 3H and I) . In addition, the upregulation of p21, BAX and PUMA proteins was confirmed by flow cytometry and immunofluorescence ( Figure 4A-F) . The flow cytometry spectral shifts in Figure 4A -C clearly indicate the increased levels of the target proteins. Further, the immunostaining of SKBR3 cells with the same antibodies used for flow cytometry confirmed the upregulation of the p21, Bax and Puma proteins after GON treatment (Figure 4 D-F) .
To validate the key role of GON in restoring the biological function of mutant p53 to transactivate its target genes, we treated p53 null and p53
R175H transfected H1299 cells with GON and analyzed for the expression of p21 protein. Figure 4G shows that the level of p21 protein in p53 null cells following treatment was comparable to the basal level, whereas, higher levels of p21 was observed with the H1299 (p53 R175H ) cells. Moreover, the Pifithrin-α, a specific inhibitor of p53-dependent transactivation (41) blocked the GONinduced expression of p21 in H1299 (p53 R175H ) cells ( Figure 4H ). The results presented in this section clearly demonstrate that GON was able to restore of the wild-type conformation to the R175H mutant p53 protein and confer the transcriptional activation activity associated with the normal tumor suppressor.
GON induces senescence
The CDK inhibitor p21 was initially identified as a p53-inducible protein in senescent cells (42) and was shown to trigger a stable growth arrest and senescence. Therefore, to test the hypothesis that the observed p21 induction through p53 reactivation by GON may cause senescence in SKBR3 cells, we analyzed SAβ-gal activity, a marker of cellular senescence. In agreement, GON affected the cell morphology and significantly increased Saβ-gal staining after 48 h of GON treatment, indicating that GON led to accelerated senescence through p21 induction by the reactivated p53 in SKBR3 cells ( Figure 4I ). DEP1, NTAL and STX4 and a few other proteins were identified in 2014 as novel markers of senescence in an elegant proteomics study (43) . Hence, we analyzed the expression of these membrane proteins in permeabilized SKBR3 cells by immunostaining and western blotting. The representative photomicrographs shown in Figure 4J surely indicated a discernible upregulation of these marker proteins in GON-treated cells. Parallel western blotting performed from the GON-treated senescent cells confirmed the increase of the DEP1, NTAL and Styx proteins ( Figure 4K ) indicating senescence and growth arrest as a cytotoxic mechanism of GON.
GON-induced cell cycle changes and cell death by apoptosis
In cell cycle analysis by flow cytometry using propidium iodide staining of SKBR3 cells, GON increased the G2/M population (Supplementary Figure 2 , available at Carcinogenesis Online). To characterize the mode of cell death induced by GON, a biparametric cytofluorimetric analysis was performed using propidium iodide (PI) and FITC labeled annexin-V. After GON treatment, the SKBR3 cells were labeled with the two dyes and the resulting red (PI) and green (FITC) fluorescence were monitored by flow cytometry. As presented in Figure 4L and Supplementary Figure 2B , available at Carcinogenesis Online, GON triggered an accumulation of apoptotic cells in a concentration-dependent manner after 24 h treatment. Furthermore, consistent with the observed apoptosis, the mechanistic players involved, namely, the cleaved caspases and its enzymatic product, the cleaved PARP (poly ADP-ribose polymerase) were expressed at higher levels along with reduction in anti-apoptotic proteins such as survivin and Bcl2 with GON treatment, again in a concentrationdependent manner ( Figure 4M ).
GON suppresses SKBR3 cell migration and invasion
We examined the effects of GON on the ability of SKBR3 cell migration and invasion invitro. In the scratch-wound healing assay, cells along the wound-edge would migrate into the nude space after scratching and the scratch-wound wound heals continuously (represented by reduced scratch-wound sizes between the opposite scratching lines). In SKBR3 cells GON prominently inhibited cell migration and reduced wound healing speed at 24 h of GON treatment in a 2. 
GON cisplatin combination exerts synergistic cytotoxicity
Cisplatin induces cytotoxicity by generating intrastrand and interstrand DNA crosslinks and at least in part by generating oxidative stress (44) . Therefore, we determined the synergistic effects of GON and cisplatin (CP). Individually, GON and CP exerted growth inhibition and cell death in SKBR3 cells. In combination, however, GON increased the cytotoxic activity of cisplatin inhibiting the growth to an extent greater than the sum of either agent alone ( Figure 5A ). To further confirm this synergistic effect, the cytotoxicity of GON alone or in combination with CP was evaluated in SKBR3 cells using a clonogenic assay.
Exposure to the combination of GON and cisplatin resulted in a significant decrease in colony number compared with cisplatin alone for all concentrations of GON used ( Figure 5B and C) . Next, synergism between GON and CP was analyzed using the software Compusyn as previously described (45) . The results presented in Figure 5D suggest that combination treatment on SKBR3 cells were synergistic, and this effect can be observed with the CI and DRI values. The CI values represent the quantitative interaction between the drugs and were calculated using Compusyn software at different Fa levels. The combination of GON and CP produced an explicit synergistic effect and had a CI value of less than 1 at most Fa levels. The synergism was particularly obvious at lower inhibitory concentrations, whereas little impact was observed at higher concentrations. The CI values were 0.36 and 0.44 when the Fa values were 0.93 and 0.89, respectively, but the CI value was 1.48 when Fa was 0.78. These values confirmed a significant synergistic in vitro antitumor effect in the majority of GON and CP combination treatments. The findings confirm the synergism of GON and CP are given in combination. Furthermore, CP increased the apoptotic markers induced by the GON in SKBR3 cells ( Figure 5E ) as well as the annexin-V positive cell population ( Figure 5F ).
In vivo antitumor activity of GON in a mouse subcutaneous SKBR3 xenograft model
After clarifying the anticancer effects and mechanisms of GON in SKBR3 cells and demonstrating the antitumor effects of GON and cisplatin alone or in combination in vitro we studied their effects in vivo. Xenograft tumors were established in female nude mice using SKBR3 cells. When the tumor volumes reached 40 mm 3 , animals were randomly divided into four groups and were administered GON (40 mg/kg) or cisplatin (3 mg/kg) daily through intraperitoneal injections as monotherapy, or as combination therapy at indicated doses. As demonstrated in Figure 6A , cisplatin treatment alone did not delay the tumor growth. However, GON alone resulted in a statistically significant inhibition of tumor growth as compared to the control. Combined GON and cisplatin treatments, however, resulted in a profound regression of the tumor mass. Of note, there were no remarkable changes in the average body weights of animals, suggesting that there was no overt toxicity ( Figure 6B ). Further, there were no significant differences in the histological findings among the treatment and control groups in any of the tissues examined including the liver, kidney, heart, spleen, and brain ( Figure 6D ); these data indicate that GON is unlikely to exert any adverse effects in host organs and tissues at therapeutically relevant doses either alone or in combination with cisplatin. Next, to demonstrate the effect of GON alone and in combination with cisplatin on p21, BAX, and Ki-67 in vivo, we evaluated expression levels in the SKBR3 tumor sections using immunohistochemistry. As shown in Figure 6C , the intratumoral p21 and BAX protein levels were significantly increased after administration of GON as a single agent or in combination with cisplatin along with decreased cell proliferation as reflected by attenuated expression of the Ki-67 marker in tumor tissues.
Discussion
The next generation of anticancer drugs will be defined by compounds that selectively kill cancer cells while leaving normal cells undisturbed. Cancer cells generate more ROS and are dependent on a highly functional antioxidant system than normal cells (46) . The enzymatic ROS detoxification systems that prevent the induction of cell death are activated in cancer cells. Therefore, targeting the stress phenotypes unique to cancer cells and their associated vulnerabilities may be a promising strategy for cancer treatment (47) .
Our study showed that GON selectively killed cancer cells by perturbing redox and ROS homeostasis, mechanism upon which the cancer cells are dependent (Figure 1 and Figure 2A-C) . The results clearly indicated that GON alkylates antioxidant GSH thus inhibiting the cellular antioxidant systems and elevates ROS. As illustrated in Supplementary Figure 1 , available at Carcinogenesis Online, GON undergoes Michael addition with the ROS quenching thiols and depletes them. Consequently, the amplification of oxidative stress as indicated by DCFDA and DHE fluorescence and co-treatment with NAC or Tyron, which quench the ROS, led to the reversal of GON-induced ROS accumulation. Based on this study we hypothesized that the electrophilicity of GON might be central to its bioactivity. Beyond elevation of ROS, GON affected other cellular markers of oxidative stress such as glutathionylation of proteins ( Figure 2F -G) GON induced a large and rapid elevation in protein glutathionylation.
p53 is the most commonly mutated gene in human cancer, and the p53R175 mutant is the third most frequently found missense mutant. Because half of all cancers carry a p53 mutation, it is imperative that we find effective cures for these tumors which lack the wt tumor suppressor function. Restoration of wild-type p53 function in human cancers either by gene therapy or small molecules to induce robust cell death and allow efficient eradication of the tumor has gained much attention in years (21) (22) (23) (24) (25) . Various approaches have led to the identification of small molecules that can rescue mutant p53. Many of these chemical entities PRIMA MIRA-1, STIMA-1 and WR-1065 that effectively induce a reactivation of mutant p53 proteins in cell cultures (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) share a common feature in bearing electrophilic double bonds that participate in Micheal addition reactions. In fact, these compounds have been shown to modify the thiol groups directly by alkylation or by affecting the cellular redox state.
Human p53 is an established redox-sensitive protein (48) . Our previous studies showed that the reactive cysteines as major targets of oxidation and protective glutathionylation by ROS (46) . The cysteines 124, 141 and 182, which are critical for p53 binding to DNA were identified by us to be redox-sensitive and glutathionylation of these residues inhibited DNA binding (49) . In support of our findings, Cys141 oxidation through a charge transfer in DNA was shown to prevent the physical binding of p53 to DNA (50) . Cys141-glutathionylation specific antibodies developed in our laboratory (51) should aid these studies further. Wassman et al. (52) using computational and biological studies have demonstrated that the redox-sensitive cys124 is indeed a critical residue for reactivation of the R175H mutant p53 protein mediating conformational changes in the L1/S3 binding pocket. Several studies from our laboratory (31, 32, 50) further lend credence to the concept that induction of moderate oxidative stress in tumor cells can alter the folding of mutant p53 proteins and favor the acquisition of a wild-type-like confirmation. These studies used a hybrid drug bearing the piperlongumine pharmacophore (31), piperlongumine itself (32) and the other, a cisplatin-stabilized homoglutathione disulfide (53) . All of these compounds triggered discernible levels of ROS, protein thiolation and reactivation of R273H and R175H p53 mutants in cell lines and in subcutaneous xenografts after compound administrations.
A pharmacological reactivation of p53 mutants remains a viable and feasible strategy for improving cancer therapies. Because the mutant proteins are present at high levels in tumor cells, even a small portion of activated protein can be hugely apoptotic. Further, unlike the wild-type p53 proteins, site-specific phosphorylations and acetylations may not be involved in restoring functionality. The activated mutant proteins may retain a longer half-life and not targeted for ubiquitin-mediated proteolysis by MDM2. In view of the structural similarity of GON with the reported mutant p53 reactivating molecules in having an active double bond with an affinity for nucleophilic sites, we hypothesized that the increased activity may result from the functional restoration of the p53, mediated either through a change in cellular redox or a direct interaction with the tumor suppressor. In support, the current study provided multiple lines of evidence involving immunocytochemistry, EMSA, induction of target gene expression, apoptosis, senescence and increased anticancer efficacy both in vitro and in vivo for conferral of functionality to the R175H p53 mutant in SKBR3 cells by GON. Many of the results were verified in H1299 cells expressing the mutant p53 proteins. The ability of GON to reactivate the p53 R175H mutant described here adds to the list of compounds and confirms our hypothesis that generation of a transitional redox stress at minimal to moderate levels offers a mechanistic platform to restore the biological activity to mutant p53 proteins. Additionally, GON and its superior analogs are likely be useful in cancer therapy in view of a long-term use of the metabolite for medicinal purposes, lack of significant toxicity, ability to generate ROS and synergize with commonly used anticancer drugs such as cisplatin.
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Supplementary materials can be found at Carcinogenesis online. 
